Product information and disease descriptionProduct descriptionProduct information
Dosing and administration
19 evidence topics · 19 sources
RP-A501 (AAV9.LAMP2B)
Danon disease
- Manufacturer
- Rocket Pharmaceuticals
- Regulatory submission
- BLA planned for late 2028
- Launch
- Anticipated in mid-2029
- Last updated